Cancer cachexia drives a distinct cardiac wasting program in human muscle cells
Cancer cachexia is usually framed as a skeletal muscle syndrome, but the cardiac phenotype is just as biologically consequential. In a human induced pluripotent stem cell–derived cardiac myocyte model, cachexia-inducing tumor signals pushed cardiac muscle toward atrophy, impaired contraction, and altered metabolism, showing that the heart is not merely an innocent bystander to systemic cancer wasting. The experimental platform used conditioned media and Transwell coculture with C26 or HCT116 tumor cells, giving investigators a way to reproduce cachexia-associated stress in human cardiac cells rather than relying only on animal physiology. Within that setting, the cardiomyocytes did not simply shrink; they also lost functional reserve, with reduced contraction amplitude, prolonged relaxation time, and higher oxygen consumption rate. The combination points to a heart that is both mechanically weaker and metabolically overworked, a pattern that fits with the relentless catabolic pressure seen in advanced malignancy.
Cachexia can strip lean mass quickly, but cardiac impairment may linger after the inflammatory storm eases.
AKT/mTORC1 suppression sits at the center of the wasting response
The dominant signaling change involved suppression of the AKT/mTORC1/S6 axis. Total and phosphorylated AKT fell, the p-S6/S6 ratio dropped, and RPTOR expression declined as well, creating a molecular environment hostile to protein synthesis and cell maintenance. In a cardiomyocyte, that matters because AKT and mTORC1 ordinarily support anabolic signaling, preserve cellular size, and help sustain contractile integrity. When that pathway is shut down, the cell shifts away from growth and toward catabolism, and the structural consequences become visible as atrophy. The data place this pathway upstream of the broader wasting phenotype rather than treating it as a secondary epiphenomenon.
FOXO activation and Atrogin-1 help explain the structural loss
The most coherent downstream consequence was activation of FOXO1/3, including FOXO1 nuclear translocation. Once FOXO signaling entered the nucleus, atrophic remodeling followed through upregulation of Atrogin-1, a familiar mediator of protein breakdown in muscle wasting states. In practical biologic terms, FOXO activation turns on a transcriptional program that favors degradation over preservation, and the heart appears to obey that same logic under cachectic pressure. This is not a subtle molecular drift; it is a direct switch toward proteolysis. The model therefore links tumor-derived cachexia signals to a recognizable muscle-wasting axis that is now being seen in human cardiac cells rather than inferred from skeletal muscle alone.
Calcineurin A and NFAT signaling weaken alongside the catabolic program
Atrogin-1 upregulation was paired with reduced calcineurin A and impaired NFAT nuclear translocation. That second arm matters because calcineurin-NFAT signaling supports growth-related transcription, and its suppression removes another layer of protection against wasting. The interaction between these pathways creates a feed-forward injury pattern: reduced anabolic drive through AKT/mTORC1, increased catabolic transcription through FOXO, and weakened pro-growth signaling through calcineurin/NFAT. In the heart, that combination is especially damaging because cardiomyocytes have limited regenerative capacity and depend heavily on coordinated protein turnover to maintain contractile apparatus and calcium handling. The result is not just smaller cells, but cells less able to relax and contract efficiently.
Autophagy rises while function deteriorates
The model also showed increased autophagic flux, reflected by an elevated LC3BII/LC3BI ratio. Autophagy is not inherently harmful; in many settings it helps cells recycle damaged components and adapt to stress. Under persistent cachectic stimulation, however, elevated autophagy can become part of the wasting machinery rather than a rescue mechanism. Here, the rise in autophagy markers tracked with atrophy and declining function, not recovery. Elevated oxygen consumption rate suggested that the cardiomyocytes were burning more energy while becoming less efficient, a mismatch that can deepen cellular exhaustion. In a patient with cancer, that kind of energetic inefficiency could help explain why cardiac reserve erodes even when overt heart failure is not the presenting complaint.
Recovery of signaling did not mean recovery of performance
Removal of the cachexia-inducing stimuli normalized Atrogin-1 and autophagy markers within 1 week, yet contractile and metabolic impairments persisted. That dissociation is the most clinically arresting part of the dataset. Molecular markers moved back toward baseline, but the cells did not instantly regain normal function, implying that structural or energetic injury outlasted the initial signaling insult. For bedside medicine, the implication is straightforward: reversing the catabolic trigger may not be enough to restore cardiac performance once the wasting phenotype has taken hold. The myocardium may carry a biologic memory of cachexia, with delayed recovery even after the external stress is withdrawn.
This persistence argues for earlier intervention, before the contractile defect becomes entrenched.
Why this cardiac cachexia axis matters for cancer care
Cancer cachexia is often discussed through weight loss, frailty, and skeletal muscle decline, yet these findings place the heart inside the same wasting circuit. A patient can lose cardiac performance without a classic ischemic event or overt cardiomyopathy, simply because systemic tumor signaling has pushed myocardial cells into a catabolic state. The human iPSC platform strengthens that interpretation by showing the phenotype in human cardiac muscle cells exposed to tumor-conditioned cues. It also provides a tractable experimental system for testing therapies that might block AKT/mTORC1 suppression, blunt FOXO activation, restrain Atrogin-1 induction, or preserve calcineurin/NFAT signaling. Each of those nodes offers a plausible point of intervention, but the data also warn that timing will matter, because functional recovery appears slower than molecular recovery.
The study does not answer how these pathways behave in patients over time, how much reversibility remains after prolonged cachexia, or which intervention would best preserve cardiac function. It does, however, define a coherent human cardiac wasting program and places the FOXO/Atrogin-1/calcineurin A/NFAT axis, operating within the broader context of AKT/mTORC1 suppression, at the center of the biology.